Skip to main content

Closed

ENLV: Enlivex Therapeutics Ltd. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-0.5%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio193.24×

Valuation

Unrated

P/E ratio0.0×

Enlivex Therapeutics Ltd.

ENLVNASDAQ Capital Market·USD·Closed

Enlivex Therapeutics Ltd.

ENLVNASDAQ·USD·Closed

$2.09

+7.18%

$2.09

+$0.14 (7.18%)

52W Range

1thpctl

Volume

2.96×avg

Mkt Cap

35.18MUSD

P/E

0.0TTM

Div Yield

–ann

52W Range

1thpctl

Volume

2.96×avg

Market Cap

35.18MUSD

P/E Ratio

0.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings